vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and OP Bancorp (OPBK). Click either name above to swap in a different company.
OP Bancorp is the larger business by last-quarter revenue ($24.3M vs $15.0M, roughly 1.6× CHAMPIONS ONCOLOGY, INC.). On growth, OP Bancorp posted the faster year-over-year revenue change (13.7% vs 11.5%). OP Bancorp produced more free cash flow last quarter ($23.4M vs $-2.0M). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs 11.4%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
OP Bancorp is the bank holding company for Open Bank, a community-oriented commercial bank headquartered in California, United States. It provides a full range of banking solutions including deposit accounts, commercial real estate loans, small business financing, and consumer lending products, primarily catering to small and medium-sized enterprises, local immigrant communities, and retail clients across Southern California.
CSBR vs OPBK — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $24.3M |
| Net Profit | $268.0K | — |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | 39.2% |
| Net Margin | 1.8% | — |
| Revenue YoY | 11.5% | 13.7% |
| Net Profit YoY | -63.2% | — |
| EPS (diluted) | $0.02 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $24.3M | ||
| Q3 25 | $14.0M | $24.5M | ||
| Q2 25 | $12.4M | $23.7M | ||
| Q1 25 | $17.0M | $22.2M | ||
| Q4 24 | $13.5M | $21.3M | ||
| Q3 24 | $14.1M | $20.7M | ||
| Q2 24 | $14.0M | $20.4M | ||
| Q1 24 | $12.0M | $19.6M |
| Q4 25 | $268.0K | — | ||
| Q3 25 | $-436.0K | $6.7M | ||
| Q2 25 | $-1.8M | $6.3M | ||
| Q1 25 | $4.5M | $5.6M | ||
| Q4 24 | $728.0K | — | ||
| Q3 24 | $1.3M | $5.4M | ||
| Q2 24 | $-109.0K | $5.4M | ||
| Q1 24 | $-2.5M | $5.2M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | 39.2% | ||
| Q3 25 | -3.8% | 39.5% | ||
| Q2 25 | -16.2% | 35.7% | ||
| Q1 25 | 26.4% | 34.6% | ||
| Q4 24 | 5.4% | 31.2% | ||
| Q3 24 | 9.5% | 36.5% | ||
| Q2 24 | -1.9% | 37.2% | ||
| Q1 24 | -21.4% | 37.1% |
| Q4 25 | 1.8% | — | ||
| Q3 25 | -3.1% | 27.4% | ||
| Q2 25 | -14.9% | 26.7% | ||
| Q1 25 | 26.4% | 25.0% | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 9.3% | 26.2% | ||
| Q2 24 | -0.8% | 26.7% | ||
| Q1 24 | -21.1% | 26.7% |
| Q4 25 | $0.02 | $0.48 | ||
| Q3 25 | $-0.03 | $0.45 | ||
| Q2 25 | $-0.12 | $0.42 | ||
| Q1 25 | $0.31 | $0.37 | ||
| Q4 24 | $0.05 | $0.33 | ||
| Q3 24 | $0.09 | $0.36 | ||
| Q2 24 | $-0.01 | $0.36 | ||
| Q1 24 | $-0.19 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $167.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $227.9M |
| Total Assets | $30.2M | $2.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $167.3M | ||
| Q3 25 | $10.3M | $166.7M | ||
| Q2 25 | $9.8M | $205.4M | ||
| Q1 25 | $3.2M | $198.9M | ||
| Q4 24 | $2.8M | $134.9M | ||
| Q3 24 | $2.9M | $166.8M | ||
| Q2 24 | $2.6M | $127.7M | ||
| Q1 24 | $4.5M | $139.2M |
| Q4 25 | $4.2M | $227.9M | ||
| Q3 25 | $3.5M | $221.5M | ||
| Q2 25 | $3.8M | $213.7M | ||
| Q1 25 | $5.5M | $210.1M | ||
| Q4 24 | $681.0K | $205.0M | ||
| Q3 24 | $-332.0K | $203.6M | ||
| Q2 24 | $-1.9M | $195.9M | ||
| Q1 24 | $-2.1M | $194.7M |
| Q4 25 | $30.2M | $2.7B | ||
| Q3 25 | $30.5M | $2.6B | ||
| Q2 25 | $32.3M | $2.6B | ||
| Q1 25 | $30.6M | $2.5B | ||
| Q4 24 | $25.2M | $2.4B | ||
| Q3 24 | $24.9M | $2.4B | ||
| Q2 24 | $26.1M | $2.3B | ||
| Q1 24 | $26.8M | $2.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $26.2M |
| Free Cash FlowOCF − Capex | $-2.0M | $23.4M |
| FCF MarginFCF / Revenue | -13.1% | 96.2% |
| Capex IntensityCapex / Revenue | 1.6% | 11.5% |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $43.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $26.2M | ||
| Q3 25 | $600.0K | $23.9M | ||
| Q2 25 | $6.9M | $-7.0M | ||
| Q1 25 | $490.0K | $5.6M | ||
| Q4 24 | $-283.0K | $31.2M | ||
| Q3 24 | $311.0K | $13.3M | ||
| Q2 24 | $-1.8M | $15.8M | ||
| Q1 24 | $-919.0K | $-3.2M |
| Q4 25 | $-2.0M | $23.4M | ||
| Q3 25 | $554.0K | $23.4M | ||
| Q2 25 | $6.6M | $-7.7M | ||
| Q1 25 | $448.0K | $4.2M | ||
| Q4 24 | $-377.0K | $29.7M | ||
| Q3 24 | — | $12.8M | ||
| Q2 24 | $-1.8M | $15.7M | ||
| Q1 24 | $-1.0M | $-3.2M |
| Q4 25 | -13.1% | 96.2% | ||
| Q3 25 | 4.0% | 95.6% | ||
| Q2 25 | 53.5% | -32.5% | ||
| Q1 25 | 2.6% | 19.0% | ||
| Q4 24 | -2.8% | 139.0% | ||
| Q3 24 | — | 61.5% | ||
| Q2 24 | -13.0% | 77.0% | ||
| Q1 24 | -8.4% | -16.6% |
| Q4 25 | 1.6% | 11.5% | ||
| Q3 25 | 0.3% | 2.3% | ||
| Q2 25 | 2.0% | 3.0% | ||
| Q1 25 | 0.2% | 6.4% | ||
| Q4 24 | 0.7% | 7.3% | ||
| Q3 24 | 0.0% | 2.8% | ||
| Q2 24 | 0.0% | 0.4% | ||
| Q1 24 | 0.8% | 0.5% |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | 3.57× | ||
| Q2 25 | — | -1.10× | ||
| Q1 25 | 0.11× | 1.02× | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | 2.45× | ||
| Q2 24 | — | 2.90× | ||
| Q1 24 | — | -0.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
OPBK
Segment breakdown not available.
